Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 19c; Offers Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $92.1 million versus the consensus estimate of $90.29 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $385-390 million, versus the consensus of $385.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Cardinal Health (CAH) Tops Q4 EPS by 19c, Misses on Revenue; Offers FY27 EPS Guidance
• H.C. Wainwright Reiterates Neutral Rating on Crinetics (CRNX)
• Aramark Services (ARMK) Tops Q3 EPS by 4c, Beats on Revenue; Offers Guidance